Denali officer sells 2,768 shares under plan

Denali Therapeutics’ COFO and Secretary sold 2,768 DNLI shares under a Rule 10b5-1 plan while retaining substantial direct and trust holdings.

Rhea-AI Filing Summary

Denali Therapeutics Inc. (DNLI) reported that its COFO and Secretary, Alexander O. Schuth, sold 2,768 shares of Common Stock on September 1, 2026 at $23.44 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. After this transaction, Schuth directly held 278,995 shares, including 135,475 unvested RSUs, and indirectly held 523,749 shares through The Schuth Family Trust, for which he serves as trustee.

Insider Trade Summary 10b5-1

Net Seller: 2,768 shares

Net Sell 2 txns

Insider Schuth Alexander O.

Role COFO and Secretary

Sold 2,768 shs ($65K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,768	$23.44	$65K
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 278,995 shares (Direct); Common Stock — 523,749 shares (Indirect, See footnote)

Footnotes (3)

1. F1. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
2. F2. Includes 135,475 Unvested RSUs.
3. F3. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Key Figures

Shares sold: 2,768 shares Sale price per share: $23.44 per share Direct holdings after transaction: 278,995 shares +3 more

6 metrics

Shares sold 2,768 shares Common Stock sale on September 1, 2026

Sale price per share $23.44 per share Price for the 2,768 DNLI shares sold on September 1, 2026

Direct holdings after transaction 278,995 shares Direct Common Stock holdings of Alexander O. Schuth after the sale

Unvested RSUs included in direct holdings 135,475 RSUs Unvested RSUs included within the 278,995 directly held shares

Indirect holdings after transaction 523,749 shares Shares held by The Schuth Family Trust for which Schuth is trustee

Rule 10b5-1 plan adoption date March 27, 2026 Adoption date of the trading plan under which the sale was made

Key Terms

Rule 10b5-1 trading plan, Unvested RSUs, indirect, trustee

4 terms

Rule 10b5-1 trading plan regulatory

"sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Unvested RSUs financial

"Includes 135,475 Unvested RSUs."

indirect financial

"The shares are held of record by The Schuth Family Trust"

trustee financial

"for which the Reporting Person serves as trustee."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Denali Therapeutics (DNLI) disclose for Alexander O. Schuth?

Denali Therapeutics disclosed that Alexander O. Schuth, COFO and Secretary, sold 2,768 shares of Common Stock on September 1, 2026 in an open-market or private transaction at $23.44 per share.

Was the September 1, 2026 DNLI share sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan that was adopted March 27, 2026, indicating the trades were pre-arranged under that plan.

How many DNLI shares does Alexander O. Schuth hold directly after this Form 4 transaction?

After the reported sale, Alexander O. Schuth directly holds 278,995 shares of Denali Therapeutics Common Stock, which the filing notes includes 135,475 unvested RSUs.

What are Alexander O. Schuth’s indirect DNLI holdings following the transaction?

Following the transaction, Alexander O. Schuth has 523,749 shares held indirectly, recorded in the name of The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee.

What role does Alexander O. Schuth hold at Denali Therapeutics (DNLI)?

The filing identifies Alexander O. Schuth as an officer of Denali Therapeutics, serving as COFO and Secretary of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:29 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schuth Alexander O.

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COFO and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		2,768	D	$23.44	278,995(2)	D
Common Stock								523,749	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.

2. Includes 135,475 Unvested RSUs.

3. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)